NCT00667342 arm group 0228dbe253497cf370fbed8ca0675665 [clinicaltrials_resource:NCT00667342/arm-group/0228dbe253497cf370fbed8ca0675665]
etoposide [clinicaltrials_resource:24fa0b64d3f43099c95ce943c4945cc9]Methotrexate [clinicaltrials_resource:4e547eff981137da06134ca5808b643c]Doxorubicin [clinicaltrials_resource:6a8adb62348e1864e9650e6152c566aa]Cisplatin [clinicaltrials_resource:9874a4234f5594cc82868395a7343063]Bevacizumab [clinicaltrials_resource:c4202e745f68a1fdd802342460106e4c]Ifosfamide [clinicaltrials_resource:d0e20f7563c729a3db660ee04bc6e06e]Surgery [clinicaltrials_resource:e7cf0833399bc7ded2ada79408b35af0]Radiotherapy [clinicaltrials_resource:f95ab74755edd6e2ad60a3a1af20ac1f]clinicaltrials:NCT00667342
arm group [clinicaltrials_vocabulary:arm-group]
NCT00667342 arm group 0228dbe253497cf370fbed8ca0675665 [clinicaltrials_resource:NCT00667342/arm-group/0228dbe253497cf370fbed8ca0675665]
Bio2RDF identifier
NCT00667342/arm-group/0228dbe253497cf370fbed8ca0675665
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 28dbe253497cf370fbed8ca0675665
description [clinicaltrials_vocabulary:description]
Participants with unresectable ...... ill be given post-operatively.
identifier
clinicaltrials_resource:NCT00667342/arm-group/0228dbe253497cf370fbed8ca0675665
title
NCT00667342 arm group 0228dbe253497cf370fbed8ca0675665
@en
type
label
NCT00667342 arm group 0228dbe2 ...... 8dbe253497cf370fbed8ca0675665]
@en